• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Activity of trametinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory RAS pathway-mutated hematologic malignancies.

作者信息

Li Zhihui, Yang Keyan, Xu Teng, Wang Lei, Wang Xianxuan, Wen Xiaopei, Zhang Caiyan, Wang Jingjing, Zheng Xiaoyu, Wu Tong, Zheng Qinlong

机构信息

Department of Bone Marrow Transplantation, Beijing Gaobo Boren Hospital, Beijing, China.

Department of Medical Laboratory, Beijing Gaobo Boren Hospital, Beijing, China.

出版信息

Ann Hematol. 2025 Feb;104(2):1295-1301. doi: 10.1007/s00277-024-06046-7. Epub 2024 Oct 19.

DOI:10.1007/s00277-024-06046-7
PMID:39425789
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11971147/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b16/11971147/7ea5ab6614b1/277_2024_6046_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b16/11971147/098f9a0a2b7a/277_2024_6046_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b16/11971147/7ea5ab6614b1/277_2024_6046_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b16/11971147/098f9a0a2b7a/277_2024_6046_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b16/11971147/7ea5ab6614b1/277_2024_6046_Fig2_HTML.jpg

相似文献

1
Activity of trametinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory RAS pathway-mutated hematologic malignancies.曲美替尼作为复发或难治性RAS通路突变血液系统恶性肿瘤患者异基因造血干细胞移植后维持治疗的活性。
Ann Hematol. 2025 Feb;104(2):1295-1301. doi: 10.1007/s00277-024-06046-7. Epub 2024 Oct 19.
2
Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.供体CIK细胞输注后异基因造血干细胞移植：一项针对复发/难治性血液系统恶性肿瘤患者的I期研究。
Leuk Res. 2016 Sep;48:6-10. doi: 10.1016/j.leukres.2016.06.006. Epub 2016 Jun 23.
3
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.口服丝裂原活化蛋白激酶激酶抑制剂曲美替尼在RAS突变的复发或难治性髓系恶性肿瘤中的活性
Cancer. 2016 Jun 15;122(12):1871-9. doi: 10.1002/cncr.29986. Epub 2016 Mar 18.
4
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.对晚期血液系统恶性肿瘤患者进行非清髓性预处理的异基因造血细胞移植。
Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880.
5
[Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].[首次异基因造血干细胞移植后复发血液系统恶性肿瘤的二次异基因造血干细胞移植：采用减低剂量预处理及供者变更]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):465-471. doi: 10.3760/cma.j.issn.0253-2727.2023.06.004.
6
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.变构 MEK 抑制剂曲美替尼治疗复发/难治性幼年髓单核细胞白血病的疗效：来自儿童肿瘤协作组的报告。
Cancer Discov. 2024 Sep 4;14(9):1590-1598. doi: 10.1158/2159-8290.CD-23-1376.
7
Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.在自体干细胞移植后复发的血液系统恶性肿瘤患者中，采用非清髓性预处理进行成功的异基因干细胞移植。
Biol Blood Marrow Transplant. 2001;7(11):604-12. doi: 10.1053/bbmt.2001.v7.pm11760148.
8
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.阿扎胞苷、维奈克拉和曲美替尼治疗携带RAS通路激活突变的复发或难治性急性髓系白血病的II期研究。
Acta Haematol. 2022;145(5):529-536. doi: 10.1159/000525566. Epub 2022 Jun 17.
9
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.异基因造血干细胞移植后在B细胞恶性肿瘤中输注异基因CD19嵌合抗原受体T细胞。
J Hematol Oncol. 2017 Jan 31;10(1):35. doi: 10.1186/s13045-017-0405-3.
10
Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.供体来源 CD7 CAR-T 治疗联合异基因造血干细胞移植治疗乙型肝炎相关急性 T 淋巴细胞白血病：一例报告。
Front Immunol. 2022 Jul 12;13:931452. doi: 10.3389/fimmu.2022.931452. eCollection 2022.

引用本文的文献

1
A reduced-toxicity myeloablative conditioning approach for hematopoietic cell transplant in juvenile myelomonocytic leukemia.用于青少年骨髓单核细胞白血病造血细胞移植的低毒性清髓预处理方法。
Front Oncol. 2025 Jun 3;15:1541192. doi: 10.3389/fonc.2025.1541192. eCollection 2025.

本文引用的文献

1
Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure.原发性诱导失败后行异基因造血干细胞移植治疗的急性髓系白血病患者的长期随访。
Blood Cancer J. 2023 Dec 10;13(1):179. doi: 10.1038/s41408-023-00953-0.
2
CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results.嵌合抗原受体T细胞（CAR-T）疗法联合异基因造血干细胞移植治疗难治性/复发性急性B淋巴细胞白血病：长期随访结果
Front Oncol. 2023 Jan 4;12:1048296. doi: 10.3389/fonc.2022.1048296. eCollection 2022.
3
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
达拉非尼联合曲美替尼治疗复发性/难治性 BRAF V600E 突变阳性毛细胞白血病患者。
Blood. 2023 Mar 2;141(9):996-1006. doi: 10.1182/blood.2021013658.
4
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.阿扎胞苷、维奈克拉和曲美替尼治疗携带RAS通路激活突变的复发或难治性急性髓系白血病的II期研究。
Acta Haematol. 2022;145(5):529-536. doi: 10.1159/000525566. Epub 2022 Jun 17.
5
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis.二十年来异基因干细胞移植治疗复发/难治性急性髓系白血病的纵向结局：ALWP/EBMT 分析。
Clin Cancer Res. 2022 Oct 3;28(19):4258-4266. doi: 10.1158/1078-0432.CCR-22-0809.
6
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.RAS 激活诱导急性髓系白血病中线粒体氧化代谢的 MEK 抑制合成致死性。
Leukemia. 2022 May;36(5):1237-1252. doi: 10.1038/s41375-022-01541-0. Epub 2022 Mar 30.
7
Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.RAS 通路改变在儿童急性髓系白血病中的临床意义。
Haematologica. 2022 Mar 1;107(3):583-592. doi: 10.3324/haematol.2020.269431.
8
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.异基因移植后急性淋巴细胞白血病患者的生存预后因素。
Bone Marrow Transplant. 2021 Apr;56(4):841-852. doi: 10.1038/s41409-020-01101-z. Epub 2020 Oct 31.
9
Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis.异基因造血细胞移植治疗复发/难治性急性淋巴细胞白血病患者的结局和预后因素：一项 KSGCT 多中心分析。
Biol Blood Marrow Transplant. 2020 May;26(5):998-1004. doi: 10.1016/j.bbmt.2020.01.007. Epub 2020 Jan 18.
10
Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.诱导多能干细胞揭示幼年髓单核细胞白血病的突变特异性信号谱和激酶抑制剂敏感性。
Leukemia. 2019 Jan;33(1):181-190. doi: 10.1038/s41375-018-0169-y. Epub 2018 Jun 8.